FindTrial
Sign In

Research on Artificial Intelligence-Based PET/CT and Pathological Multimodal Automatic Segmentation and Prognostic Evaluation in Hodgkin's Lymphoma

Research on Artificial Intelligence-Based PET/CT and Pathological Multimodal Automatic Segmentation and Prognostic Evaluation in Hodgkin's Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111886
Enrollment
Unknown
Registered
2025-11-07
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hodgkin Lymphoma

Interventions

Case series:none

Sponsors

Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 99 Years

Inclusion criteria

Inclusion criteria: 1. Histopathologically confirmed as Hodgkin's lymphoma; 2. 18F-FDG PET/CT examination before treatment; 3. Complete clinical pathological and follow-up data.

Exclusion criteria

Exclusion criteria: 1. The patient has previously received anti-tumor treatment; 2. Combined with other malignant tumors; 3. Incomplete clinical information or imaging data.

Design outcomes

Primary

MeasureTime frame
Radiomics score;Pathological omics indicators;AUC;—

Secondary

MeasureTime frame
Suvmax;Total Lesion Glycolysis, TLG;Total Metabolic Tumor Volume, TMTV;—

Countries

China

Contacts

Public ContactTeng yue

Drum Tower Hospital

18304636833@163.com+86 25 8310 6666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026